LAM
VRTX icon

LECAP Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LECAP Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,507
Closed -$673K – 387
2026
Q1 		$673K Buy
1,507
+262
+21% +$122K 0.25% 161
2025
Q4 		$564K Buy
+1,245
New +$537K 0.22% 163
2025
Q1 		– Sell
-1,944
Closed -$783K – 399
2024
Q4 		$783K Buy
+1,944
New +$901K 0.21% 172
2024
Q3 		– Sell
-2,449
Closed -$1.15M – 422
2024
Q2 		$1.15M Sell
2,449
-330
-12% -$143K 0.25% 160
2024
Q1 		$1.16M Buy
+2,779
New +$1.17M 0.24% 160

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LECAP Asset Management's VRTX Position: Q2 2026 in Review

LECAP Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,507 shares — an estimated $673K sold.

LECAP Asset Management first reported a position in VRTX in Q1 2024 and held it in 5 quarters. The position peaked at $1.16M in Q1 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LECAP Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LECAP Asset Management sold 1,507 Vertex Pharmaceuticals shares in Q2 2026, an estimated $673K.
  • LECAP Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • LECAP Asset Management's Vertex Pharmaceuticals position peaked at $1.16M in Q1 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LECAP Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.